Skip to main content
Erschienen in: Der Pathologe 1/2016

01.02.2016 | Prostatakarzinom | Schwerpunkt: Uropathologie

Konsenskonferenz 2014 der ISUP zur Gleason-Graduierung des Prostatakarzinoms

verfasst von: Prof. Dr. G. Kristiansen, L. Egevad, M. Amin, B. Delahunt, J. R. Srigley, P. A. Humphrey, J. I. Epstein, Graduierungskommittee

Erschienen in: Die Pathologie | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Im Jahr 2005 führte die internationale Gesellschaft für Urologische Pathologie (ISUP) eine Konsenskonferenz zur Gleason-Graduierung durch, um dieses Graduierungssystem auf den Stand der zeitgenössischen Praxis zu aktualisieren. Es stellte sich jedoch heraus, dass es weiteren Modifikationsbedarf zur Prostatakarzinomgraduierung gibt. Die Internationale Gesellschaft für Urologische Pathologie führte daher 2014 eine weitere Konsenskonferenz durch, um diese Punkte anzugehen. In der vorliegenden Arbeit werden die wesentlichen Ergebnisse des Chicagoer Graduierungstreffens vorgestellt.
Literatur
1.
Zurück zum Zitat Bailar JC 3rd, Mellinger GT, Gleason DF (1966) Survival rates of patients with prostatic cancer, tumor stage, and differentiation – preliminary report. Cancer Chemother Rep 1(50):129–136 Bailar JC 3rd, Mellinger GT, Gleason DF (1966) Survival rates of patients with prostatic cancer, tumor stage, and differentiation – preliminary report. Cancer Chemother Rep 1(50):129–136
2.
Zurück zum Zitat Berman DM, Epstein JI (2014) When is prostate cancer really cancer? Urol Clin North Am 41:339–346CrossRef Berman DM, Epstein JI (2014) When is prostate cancer really cancer? Urol Clin North Am 41:339–346CrossRef
3.
5.
Zurück zum Zitat Chan TY, Partin AW, Walsh PC et al (2000) Prognostic significance of Gleason score 3 + 4 versus Gleason score 4 + 3 tumor at radical prostatectomy. Urology 56:823–827CrossRef Chan TY, Partin AW, Walsh PC et al (2000) Prognostic significance of Gleason score 3 + 4 versus Gleason score 4 + 3 tumor at radical prostatectomy. Urology 56:823–827CrossRef
6.
Zurück zum Zitat D’amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974CrossRefPubMed D’amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974CrossRefPubMed
7.
Zurück zum Zitat Epstein JI, Allsbrook WC Jr, Amin MB et al (2005) The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29:1228–1242CrossRef Epstein JI, Allsbrook WC Jr, Amin MB et al (2005) The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29:1228–1242CrossRef
8.
Zurück zum Zitat Epstein JI, Feng Z, Trock BJ et al (2012) Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 61:1019–1024PubMedCentralCrossRefPubMed Epstein JI, Feng Z, Trock BJ et al (2012) Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 61:1019–1024PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Esserman LJ, Thompson IM, Reid B et al (2014) Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol 15:e234–e242PubMedCentralCrossRefPubMed Esserman LJ, Thompson IM, Reid B et al (2014) Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol 15:e234–e242PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Fine SW, Epstein JI (2008) A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score. J Urol 179:1335–1338. (discussion 1338–1339)CrossRef Fine SW, Epstein JI (2008) A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score. J Urol 179:1335–1338. (discussion 1338–1339)CrossRef
12.
Zurück zum Zitat Ghani KR, Grigor K, Tulloch DN et al (2005) Trends in reporting Gleason score 1991 to 2001: changes in the pathologist’s practice. Eur Urol 47:196–201CrossRefPubMed Ghani KR, Grigor K, Tulloch DN et al (2005) Trends in reporting Gleason score 1991 to 2001: changes in the pathologist’s practice. Eur Urol 47:196–201CrossRefPubMed
13.
Zurück zum Zitat Gleason DF (1966) Classification of prostatic carcinomas. Cancer Chemothe Rep 50:125–128 Gleason DF (1966) Classification of prostatic carcinomas. Cancer Chemothe Rep 50:125–128
14.
Zurück zum Zitat Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58–64PubMed Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58–64PubMed
15.
Zurück zum Zitat Gonzalgo ML, Bastian PJ, Mangold LA et al (2006) Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. Urology 67:115–119CrossRefPubMed Gonzalgo ML, Bastian PJ, Mangold LA et al (2006) Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. Urology 67:115–119CrossRefPubMed
16.
Zurück zum Zitat Grober ED, Tsihlias J, Jewett MA et al (2004) Correlation of the primary Gleason pattern on prostate needle biopsy with clinico-pathological factors in Gleason 7 tumors. Can J Urol 11:2157–2162PubMed Grober ED, Tsihlias J, Jewett MA et al (2004) Correlation of the primary Gleason pattern on prostate needle biopsy with clinico-pathological factors in Gleason 7 tumors. Can J Urol 11:2157–2162PubMed
17.
Zurück zum Zitat Guo CC, Epstein JI (2006) Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance. Mod Pathol 19:1528–1535CrossRefPubMed Guo CC, Epstein JI (2006) Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance. Mod Pathol 19:1528–1535CrossRefPubMed
18.
Zurück zum Zitat Helpap B, Egevad L (2006) The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens. Virchows Arch 449:622–627CrossRefPubMed Helpap B, Egevad L (2006) The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens. Virchows Arch 449:622–627CrossRefPubMed
19.
Zurück zum Zitat Iczkowski KA, Torkko KC, Kotnis GR et al (2011) Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. Am J Clin Pathol 136:98–107PubMedCentralCrossRefPubMed Iczkowski KA, Torkko KC, Kotnis GR et al (2011) Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. Am J Clin Pathol 136:98–107PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Kang DE, Fitzsimons NJ, Presti JC Jr et al (2007) Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database. Urology 70:277–282PubMedCentralCrossRefPubMed Kang DE, Fitzsimons NJ, Presti JC Jr et al (2007) Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database. Urology 70:277–282PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Khani F, Epstein JI (2015) Prostate Biopsy Specimens with Gleason 3 + 3 = 6 and Intraductal Carcinoma: radical Prostatectomy findings and clinical outcomes. Am J Surg Pathol 39:1383–1389CrossRefPubMed Khani F, Epstein JI (2015) Prostate Biopsy Specimens with Gleason 3 + 3 = 6 and Intraductal Carcinoma: radical Prostatectomy findings and clinical outcomes. Am J Surg Pathol 39:1383–1389CrossRefPubMed
22.
Zurück zum Zitat Kimura K, Tsuzuki T, Kato M et al (2014) Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate 74:680–687CrossRefPubMed Kimura K, Tsuzuki T, Kato M et al (2014) Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate 74:680–687CrossRefPubMed
23.
Zurück zum Zitat Kir G, Sarbay BC, Gumus E et al (2014) The association of the cribriform pattern with outcome for prostatic adenocarcinomas. Pathol Res Pract 210:640–644CrossRefPubMed Kir G, Sarbay BC, Gumus E et al (2014) The association of the cribriform pattern with outcome for prostatic adenocarcinomas. Pathol Res Pract 210:640–644CrossRefPubMed
24.
Zurück zum Zitat Kovi J, Jackson MA, Heshmat MY (1985) Ductal spread in prostatic carcinoma. Cancer 56:1566–1573CrossRefPubMed Kovi J, Jackson MA, Heshmat MY (1985) Ductal spread in prostatic carcinoma. Cancer 56:1566–1573CrossRefPubMed
25.
Zurück zum Zitat Kryvenko ON, Gupta NS, Virani N et al (2013) Gleason score 7 adenocarcinoma of the prostate with lymph node metastases: analysis of 184 radical prostatectomy specimens. Arch Pathol Lab Med 137:610–617CrossRefPubMed Kryvenko ON, Gupta NS, Virani N et al (2013) Gleason score 7 adenocarcinoma of the prostate with lymph node metastases: analysis of 184 radical prostatectomy specimens. Arch Pathol Lab Med 137:610–617CrossRefPubMed
26.
Zurück zum Zitat Kweldam CF, Wildhagen MF, Steyerberg EW et al (2015) Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Mod Pathol 28:457–464CrossRefPubMed Kweldam CF, Wildhagen MF, Steyerberg EW et al (2015) Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Mod Pathol 28:457–464CrossRefPubMed
27.
Zurück zum Zitat Lane BR, Magi-Galluzzi C, Reuther AM et al (2006) Mucinous adenocarcinoma of the prostate does not confer poor prognosis. Urology 68:825–830CrossRefPubMed Lane BR, Magi-Galluzzi C, Reuther AM et al (2006) Mucinous adenocarcinoma of the prostate does not confer poor prognosis. Urology 68:825–830CrossRefPubMed
28.
Zurück zum Zitat Latour M, Amin MB, Billis A et al (2008) Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathology. Am J Surg Pathol 32:1532–1539CrossRefPubMed Latour M, Amin MB, Billis A et al (2008) Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathology. Am J Surg Pathol 32:1532–1539CrossRefPubMed
29.
Zurück zum Zitat Lau WK, Blute ML, Bostwick DG et al (2001) Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. J Urol 166:1692–1697CrossRefPubMed Lau WK, Blute ML, Bostwick DG et al (2001) Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. J Urol 166:1692–1697CrossRefPubMed
30.
31.
Zurück zum Zitat Makarov DV, Sanderson H, Partin AW et al (2002) Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? J Urol 167:2440–2442CrossRefPubMed Makarov DV, Sanderson H, Partin AW et al (2002) Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? J Urol 167:2440–2442CrossRefPubMed
32.
Zurück zum Zitat Mcneal JE, Yemoto CE (1996) Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. Am J Surg Pathol 20:802–814CrossRefPubMed Mcneal JE, Yemoto CE (1996) Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. Am J Surg Pathol 20:802–814CrossRefPubMed
33.
Zurück zum Zitat Mellinger GT (1977) Prognosis of prostatic carcinoma. Recent Results Cancer Res 61–72 Mellinger GT (1977) Prognosis of prostatic carcinoma. Recent Results Cancer Res 61–72
34.
Zurück zum Zitat Mellinger GT, Gleason D, Bailar J 3rd (1967) The histology and prognosis of prostatic cancer. J Urol 97:331–337PubMed Mellinger GT, Gleason D, Bailar J 3rd (1967) The histology and prognosis of prostatic cancer. J Urol 97:331–337PubMed
35.
Zurück zum Zitat Merrick GS, Butler WM, Galbreath RW et al (2002) Biochemical outcome for hormone-naive patients with Gleason score 3 + 4 versus 4 + 3 prostate cancer undergoing permanent prostate brachytherapy. Urology 60:98–103CrossRef Merrick GS, Butler WM, Galbreath RW et al (2002) Biochemical outcome for hormone-naive patients with Gleason score 3 + 4 versus 4 + 3 prostate cancer undergoing permanent prostate brachytherapy. Urology 60:98–103CrossRef
36.
Zurück zum Zitat Miyai K, Divatia MK, Shen SS et al (2014) Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between „precursor-like“ and „regular type“ lesions. Int J Clin Exper Pathol 7:2518–2526 Miyai K, Divatia MK, Shen SS et al (2014) Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between „precursor-like“ and „regular type“ lesions. Int J Clin Exper Pathol 7:2518–2526
37.
Zurück zum Zitat Osunkoya AO, Nielsen ME, Epstein JI (2008) Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases. Am J Surg Pathol 32:468–472CrossRefPubMed Osunkoya AO, Nielsen ME, Epstein JI (2008) Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases. Am J Surg Pathol 32:468–472CrossRefPubMed
38.
Zurück zum Zitat Pierorazio PM, Walsh PC, Partin AW et al (2013) Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 111:753–760PubMedCentralCrossRefPubMed Pierorazio PM, Walsh PC, Partin AW et al (2013) Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 111:753–760PubMedCentralCrossRefPubMed
39.
Zurück zum Zitat Resnick MJ, Koyama T, Fan KH et al (2013) Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 368:436–445PubMedCentralCrossRefPubMed Resnick MJ, Koyama T, Fan KH et al (2013) Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 368:436–445PubMedCentralCrossRefPubMed
40.
Zurück zum Zitat Robinson BD, Epstein JI (2010) Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings. J Urol 184:1328–1333CrossRefPubMed Robinson BD, Epstein JI (2010) Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings. J Urol 184:1328–1333CrossRefPubMed
41.
Zurück zum Zitat Ross HM, Kryvenko ON, Cowan JE et al (2012) Do adenocarcinomas of the prostate with Gleason score (GS) ≤ 6 have the potential to metastasize to lymph nodes? Am J Surg Pathol 36:1346–1352PubMedCentralCrossRefPubMed Ross HM, Kryvenko ON, Cowan JE et al (2012) Do adenocarcinomas of the prostate with Gleason score (GS) ≤ 6 have the potential to metastasize to lymph nodes? Am J Surg Pathol 36:1346–1352PubMedCentralCrossRefPubMed
42.
Zurück zum Zitat Sabolch A, Feng FY, Daignault-Newton S et al (2011) Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys 81:e351–e360CrossRefPubMed Sabolch A, Feng FY, Daignault-Newton S et al (2011) Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys 81:e351–e360CrossRefPubMed
43.
Zurück zum Zitat Sakr WA, Tefilli MV, Grignon DJ et al (2000) Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology 56:730–734CrossRefPubMed Sakr WA, Tefilli MV, Grignon DJ et al (2000) Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology 56:730–734CrossRefPubMed
44.
Zurück zum Zitat Sarbay BC, Kir G, Topal CS et al (2014) Significance of the cribriform pattern in prostatic adenocarcinomas. Pathol Res Pract 210:554–557CrossRefPubMed Sarbay BC, Kir G, Topal CS et al (2014) Significance of the cribriform pattern in prostatic adenocarcinomas. Pathol Res Pract 210:554–557CrossRefPubMed
45.
Zurück zum Zitat Spratt DE, Zumsteg Z, Ghadjar P et al (2013) Prognostic importance of Gleason 7 disease among patients treated with external beam radiation therapy for prostate cancer: results of a detailed biopsy core analysis. Int J Radiat Oncol Biol Phys 85:1254–1261CrossRefPubMed Spratt DE, Zumsteg Z, Ghadjar P et al (2013) Prognostic importance of Gleason 7 disease among patients treated with external beam radiation therapy for prostate cancer: results of a detailed biopsy core analysis. Int J Radiat Oncol Biol Phys 85:1254–1261CrossRefPubMed
46.
Zurück zum Zitat Stark JR, Perner S, Stampfer MJ et al (2009) Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27:3459–3464PubMedCentralCrossRefPubMed Stark JR, Perner S, Stampfer MJ et al (2009) Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27:3459–3464PubMedCentralCrossRefPubMed
47.
Zurück zum Zitat Steinberg DM, Sauvageot J, Piantadosi S et al (1997) Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 21:566–576CrossRefPubMed Steinberg DM, Sauvageot J, Piantadosi S et al (1997) Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 21:566–576CrossRefPubMed
48.
Zurück zum Zitat Stenmark MH, Blas K, Halverson S et al (2011) Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease. Int J Radiat Oncol Biol Phys 81:e335–e344CrossRefPubMed Stenmark MH, Blas K, Halverson S et al (2011) Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease. Int J Radiat Oncol Biol Phys 81:e335–e344CrossRefPubMed
49.
Zurück zum Zitat Stock RG, Cesaretti JA, Stone NN (2006) Disease-specific survival following the brachytherapy management of prostate cancer. Int J Radiat Oncol Biol Phys 64:810–816CrossRefPubMed Stock RG, Cesaretti JA, Stone NN (2006) Disease-specific survival following the brachytherapy management of prostate cancer. Int J Radiat Oncol Biol Phys 64:810–816CrossRefPubMed
50.
Zurück zum Zitat Stone NN, Stone MM, Rosenstein BS et al (2011) Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J Urol 185:495–500CrossRef Stone NN, Stone MM, Rosenstein BS et al (2011) Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J Urol 185:495–500CrossRef
51.
Zurück zum Zitat Sylvester JE, Grimm PD, Wong J et al (2011) Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: seattle experience. Int J Radiat Oncol Biol Phys 81:376–381CrossRefPubMed Sylvester JE, Grimm PD, Wong J et al (2011) Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: seattle experience. Int J Radiat Oncol Biol Phys 81:376–381CrossRefPubMed
52.
Zurück zum Zitat Trudel D, Downes MR, Sykes J et al (2014) Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. Eur J Cancer 50:1610–1616CrossRefPubMed Trudel D, Downes MR, Sykes J et al (2014) Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. Eur J Cancer 50:1610–1616CrossRefPubMed
53.
Zurück zum Zitat Van Der Kwast T, Al Daoud N, Collette L et al (2012) Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy. Eur J Cancer 48:1318–1325CrossRefPubMed Van Der Kwast T, Al Daoud N, Collette L et al (2012) Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy. Eur J Cancer 48:1318–1325CrossRefPubMed
54.
Zurück zum Zitat Watts K, Li J, Magi-Galluzzi C et al (2013) Incidence and clinicopathological characteristics of intraductal carcinoma detected in prostate biopsies: a prospective cohort study. Histopathology 63:574–579PubMed Watts K, Li J, Magi-Galluzzi C et al (2013) Incidence and clinicopathological characteristics of intraductal carcinoma detected in prostate biopsies: a prospective cohort study. Histopathology 63:574–579PubMed
55.
Zurück zum Zitat Wilt TJ, Brawer MK, Jones KM et al (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203–213PubMedCentralCrossRef Wilt TJ, Brawer MK, Jones KM et al (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203–213PubMedCentralCrossRef
56.
Zurück zum Zitat Wright JL, Salinas CA, Lin DW et al (2009) Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol 182:2702–2707PubMedCentralCrossRefPubMed Wright JL, Salinas CA, Lin DW et al (2009) Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol 182:2702–2707PubMedCentralCrossRefPubMed
57.
Zurück zum Zitat Zhao T, Liao B, Yao J et al (2015) Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer? Prostate 75:225–232CrossRefPubMed Zhao T, Liao B, Yao J et al (2015) Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer? Prostate 75:225–232CrossRefPubMed
58.
Zurück zum Zitat Zumsteg ZS, Spratt DE, Pei I et al (2013) A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol 64:895–902CrossRefPubMed Zumsteg ZS, Spratt DE, Pei I et al (2013) A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol 64:895–902CrossRefPubMed
59.
Zurück zum Zitat Epstein JI, Egevad L, Amin MB et al (2016) The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 40:244-252. Epstein JI, Egevad L, Amin MB et al (2016) The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 40:244-252.
Metadaten
Titel
Konsenskonferenz 2014 der ISUP zur Gleason-Graduierung des Prostatakarzinoms
verfasst von
Prof. Dr. G. Kristiansen
L. Egevad
M. Amin
B. Delahunt
J. R. Srigley
P. A. Humphrey
J. I. Epstein
Graduierungskommittee
Publikationsdatum
01.02.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Pathologie / Ausgabe 1/2016
Print ISSN: 2731-7188
Elektronische ISSN: 2731-7196
DOI
https://doi.org/10.1007/s00292-015-0136-6

Weitere Artikel der Ausgabe 1/2016

Der Pathologe 1/2016 Zur Ausgabe

Mitteilungen der Deutschen Gesellschaft für Pathologie

Mitteilungen der Deutschen Gesellschaft für Pathologie

Schwerpunkt: Uropathologie

Prostatakarzinom

Mitteilungen der IAP

Mitteilungen der IAP

Mitteilungen des Bundesverbandes Deutscher Pathologen e.V.

Mitteilungen des Bundesverbandes Deutscher Pathologen e.V.

Passend zum Thema

ANZEIGE

Bei Immuntherapien das erhöhte Thromboserisiko beachten

Unter modernen Systemtherapien versechsfacht sich das VTE-Risiko. Warum diese Daten relevant für die Behandlung krebsassoziierter Thrombosen sind, erläutert Prof. F. Langer im Interview. So kann es durch Immuntherapien zu inflammatorischen Syndromen z.B. im GI-Trakt kommen. Nebenwirkungen wie Durchfall oder Mukositis haben dann Einfluss auf die Wirksamkeit oraler Antikoagulantien. Aber auch in punkto Blutungsrisiko ist Vorsicht geboten. Wann hier bevorzugt NMH eingesetzt werden sollten, erläutert Prof. Langer im Interview.

ANZEIGE

CAT-Management ist ganz einfach – oder doch nicht?

Krebsassoziierte venöse Thromboembolien (CAT) haben in den vergangenen Jahren stetig zugenommen. Was hat der Anstieg mit modernen Antitumortherapien zu tun? Venöse Thromboembolien sind relevante Morbiditäts- und Mortalitätsfaktoren in der Onkologie. Besonders hoch sind die Risiken bei Tumoren des Abdominalraums. Eine antithrombotische Primärprophylaxe ist daher gerade bei gastrointestinalen (GI-) Tumoren auch im ambulanten Setting wichtig.

ANZEIGE

Management von Thromboembolien bei Krebspatienten

Die Thromboembolie ist neben Infektionen die zweithäufigste Todesursache bei Krebspatienten. Die Behandlung der CAT (cancer associated thrombosis) ist komplex und orientiert sich am individuellen Patienten. Angesichts einer Vielzahl zur Verfügung stehender medikamentöser Behandlungsoptionen finden Sie hier Video-Experteninterviews, Sonderpublikationen und aktuelle Behandlungsalgorithmen zur Therapieentscheidung auf Basis von Expertenempfehlungen.

LEO Pharma GmbH